Inclusion Criteria

          -  Participant is at least 18 years of age.

          -  Female participants of childbearing potential must have a negative serum or urine
             pregnancy test within 72 hours prior to the date of the first dose of study medication
             or be of non-childbearing potential.

          -  Participant has an ECOG performance status of less than or equal to (<=)1.

          -  Participant has adequate organ function.

        Inclusion Criteria for Participants in Part 1 and Part 2 Cohorts A, B, and C:

          -  Participant with advanced or metastatic solid tumor who meets the requirements for the
             part of the study/cohort he/she will participate in, as follows:

          -  Part 2: Histologically proven advanced (unresectable) or metastatic solid tumor that
             is measurable by computed tomography (CT) or magnetic resonance imaging (MRI) per
             RECIST version 1.1 criteria

          -  Inclusion Criteria for Participants in Part 2 Cohort D

          -  Participants with advanced or metastatic NSCLC that is measurable by CT or MRI per
             RECIST version 1.1 criteria and meet the following criteria:

          -  NSCLC histology includes squamous or non-squamous cell carcinoma.

          -  Participants have received no more than 2 prior lines of therapy, which must include a
             platinum-based chemotherapy (for example [e.g.], cisplatin, carboplatin) and an
             anti-PD-(L)1 antibody.

          -  Participants must have documented radiographic progression by RECIST version 1.1
             criteria on prior anti-programmed cell death protein (PD)-1 or anti-PD-(L)1 therapy.

          -  Biopsies - If a participant has had a biopsy prior to entering the 35-day screening
             period and within approximately 12 weeks of study treatment, that biopsy may be
             accepted as the Baseline fresh biopsy.

        Exclusion Criteria

          -  History of Grade greater than or equal to (>=)3 immune-related AE with prior
             immunotherapy, with the exception of non-clinically significant lab abnormalities.

          -  Participant has known uncontrolled central nervous system (CNS) metastases and/or
             carcinomatous meningitis.

          -  Participant has a known additional malignancy that progressed or required active
             treatment within the last 2 years. Participants with a prior or concurrent malignancy
             whose natural history or treatment does not have the potential to interfere with the
             safety or efficacy assessment of the investigational regimen may be included only
             after discussion with the Medical Monitor.

          -  Participant is considered a poor medical risk due to a serious, uncontrolled medical
             disorder, nonmalignant systemic disease or active infection requiring systemic
             therapy.

          -  Participant is pregnant or breastfeeding, or expecting to conceive children within the
             projected duration of the study, starting with the Screening Visit through 150 days
             after the last dose of study treatment.

          -  Participant has a diagnosis of immunodeficiency or is receiving systemic steroid
             therapy or any other form of immunosuppressive therapy within 7 days prior to the
             first dose of study treatment.

        Exclusion Criteria for Participants in Part 2 Cohort D

          -  A participant with negative (as determined by Central Testing Lab) or unevaluable
             TIM-3 expression from tissue obtained prior to study entry will not be eligible for
             the study.

          -  Participant has received prior therapy as defined below:

          -  Prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agent that resulted in
             permanent discontinuation due to an AE.

          -  Prior treatment with an anti-lymphocyte activation gene (LAG)-3 or anti-TIM-3.

          -  Radiologic or clinical progression <= 8 weeks after initiation of prior anti-PD-1 or
             anti-PD-L1 antibody.

          -  Participants with known epidermal growth factor receptor (EGFR) mutation, anaplastic
             lymphoma kinase (ALK) translocation, or ROS1 mutation.

          -  Participant has received a vaccine other than a vaccine against severe acute
             respiratory syndrome (SARS)-coronavirus 2 (CoV-2) infection ("Coronavirus Disease
             2019" [COVID-19]) within 7 days of planned start of study therapy. The use of all
             COVID-19 vaccines is allowed, with the exception of COVID-19 vaccines using the
             recombinant adenoviral vector platform within 30 days of planned start of study
             therapy. If a COVID-19 vaccine using this platform is to be administered within 30
             days of planned start of study therapy, this must first be discussed with and approved
             by the Sponsor's Medical Monitor.